Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Semustine, a DNA alkylating agent, is a cancer chemotherapy compound that is nephrotoxic in patients with malignant melanoma receiving adjuvant chemotherapy for the adjuvant treatment of leukemia.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 138.00 | |
5 mg | In stock | $ 397.00 | |
10 mg | In stock | $ 589.00 | |
25 mg | In stock | $ 945.00 | |
50 mg | In stock | $ 1,280.00 | |
100 mg | In stock | $ 1,730.00 | |
500 mg | In stock | $ 3,460.00 |
Description | Semustine, a DNA alkylating agent, is a cancer chemotherapy compound that is nephrotoxic in patients with malignant melanoma receiving adjuvant chemotherapy for the adjuvant treatment of leukemia. |
In vivo | Semustine (Me-CCNU) (150 mg×m(-2)×d(-1) once; oral; repeated every 28 days) treatment periods were within 2 - 6 months; follow-up period was 6 months. PFS at 6 months was 55.88% in the Me-CCNU group (P < 0.05). Overall survival rates at the end of the follow-up period were 97.30% in the Me-CCNU group (P > 0.05). Adverse events rates of Me-CCNU was 45.15% (P < 0.05).[2] |
Molecular Weight | 247.72 |
Formula | C10H18ClN3O2 |
CAS No. | 13909-09-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 45.0 mg/mL (181.7 mM), Sonication is recommended.
DMSO: 90.0 mg/mL (363.3 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Semustine 13909-09-6 DNA Damage/DNA Repair DNA Alkylator/Crosslinker inhibitor inhibit